PatientsVille.com Logo

ENCEPHALOPATHY and Metronidazole

PatientsVille

ENCEPHALOPATHY Symptoms and Causes

Creutzfeldt-Jakob disease (CJD) is a rare, degenerative brain disorder. Symptoms usually start around age 60. Memory problems, behavior changes, vision problems, and poor muscle coordination progress quickly to dementia, coma, and death. Most patients die within a year.

The three main categories of CJD are

  • Sporadic CJD, which occurs for no known reason
  • Hereditary CJD, which runs in families
  • Acquired CJD, which occurs from contact with infected tissue, usually during a medical procedure

Cattle can get a disease related to CJD called bovine spongiform Encephalopathy (BSE) or "mad cow disease." There is concern that people can get a variant of CJD from eating beef from an infected animal, but there is no direct proof to support this.

NIH: National Institute of Neurological Disorders and Stroke

Check out the latest treatments for ENCEPHALOPATHY

ENCEPHALOPATHY treatment research studies

Metronidazole clinical trials, surveys and public health registries


Find Drug Side Effect reports



Metronidazole Side Effects

Dysarthria (124)
Dizziness (124)
Vomiting (119)
Nausea (108)
Encephalopathy (106)
Diarrhoea (102)
Paraesthesia (93)
Headache (88)
Confusional State (80)
Ataxia (80)
Toxic Encephalopathy (71)
Pruritus (67)
Gait Disturbance (62)
Neuropathy Peripheral (60)
Pain (60)
Pyrexia (58)
Cerebellar Syndrome (58)
Rash (56)
Urticaria (51)
Malaise (49)
Neurotoxicity (44)
Anaphylactic Reaction (44)
Abdominal Pain (43)
Dyspnoea (42)
Anxiety (41)
Dysgeusia (41)
International Normalised Ratio Increased (39)
Asthenia (38)
Hypoaesthesia (37)
Fatigue (37)
Convulsion (34)
Somnolence (34)
Nuclear Magnetic Resonance Imaging Brain Abnormal (32)
Pain In Extremity (31)
Coordination Abnormal (31)
Arthralgia (31)
Abdominal Pain Upper (30)
Balance Disorder (30)
Clostridium Difficile Colitis (30)
Depression (30)
Chest Pain (30)
Cerebellar Ataxia (29)
Insomnia (28)
Dysphagia (27)
Condition Aggravated (27)
Feeling Abnormal (27)
Psychotic Disorder (27)
Nystagmus (26)
Liver Function Test Abnormal (26)
Muscular Weakness (25)

➢ More


Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)
Zoloft(6792)
Zyrtec(1669)

Recent Reviews

<b>Describe Your Metronidazole Experience Here:</b> after taking a total of 4 pills, 1 first day 2 second day and 1 in third day. I had symptoms begin on that second day. There was tingling in my lips with burning in my lips and tongue. T

Can I take Flagyl for a UTI?

Dentist gave me 400mg of metronidazole for toothache i feel sick and dizzy i keep going hot and cold and my skin goes red

Diagnosed with BV and started taking Flagyl orally twice per day for 7 days. In the 4th day of my treatment my period started. Had very heavy flow. No cramps but very heavy menstrual bleeding and passed large blood clots

Diahorrea, metallic taste in the mouth, burning vagina feeling sick bad stomach

Experienced palpitation

Hi just been discharged from A&amp;E. Meronidazeole 400mg. I had severe racing heart beats (resting pulse normally 53 became 90-100! and would go to 140 with no prompting). Blood pressure usually 120/60 became 135/90&gt;. Breathing was di

Hi,am 21 years old from phil. am engaging sex so many times for ten guys,time came that am discharging something unpleasant and yellow in color am shy to check a doctor so i just try to search some knowledge on net then am trying using metronidazole

I am a 18 yr old, i was pescribed metro for a infection.... 2 days into i was feeling very paranoid and frightened, last night i experienced two encounters of wide awake, shaking, grunting, crying and coldness. scareyyy :'(

I am deeply indebted to Danny Smith with his comments about metronidazole. I was also prescribed metronidazole for a tooth complaint and after experiencing dizziness and being very unwell with nausea, happened to find his remarks on the net. A

I suffered from encephalopathy. I noticed tremors, terrible headaches, lethargy and insomnia. After a few months, I began to have memory problems. My doctors thought I as depressed. Finally, things started to 'move in slow motion' and at times, I fel

ENCEPHALOPATHY Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Recruiting Hyperproteic Diet Plus Lactobacillus Reuteri and Nitazoxanide in Minimal Hepatic Encephalopathy
Conditions: Hepatic Cirrhosis;   Minimal Hepatic Encephalopathy
Interventions: Other: Auxiliary Treatment;   Dietary Supplement: Hyperproteic and fiber-rich diet;   Drug: Nitazoxanide
Outcome Measures: Reverse minimal hepatic Encephalopathy;   Prevention of progression
2 Not yet recruiting Brain Muscle Axis During Treatment of Hepatic Encephalopathy With L-ornithine L-aspartate
Conditions: Hepatic Encephalopathy;   Minimal Hepatic Encephalopathy;   Cirrhosis
Interventions: Procedure: Vastus Muscle Biopsy;   Drug: LOLA or placebo;   Other: Cognitive assessment (PHES);   Other: Cognitive Assessement (Cogstate);   Other: blood and urine sampling;   Other: Nutritional assessment;   Other: MRI brain and spectroscopy;   Other: MRI leg cross section;   Other: Functional MRI (working memory and attention tasks)
Outcome Measures: Improvement in mental state on paper and pencil Hepatic Encephalopathy score (PHES) testing and Cogstate testing (computer based cognitive assessment research tool);   Brain Volume;   Brain chemical structure;   Improvement in brain function measured by functional MRI;   Improvement in Muscle Function and increase in muscle size;   Improvement of plasma and urine metabolome
3 Unknown  The Role of Bacterial Overgrowth and Delayed Intestinal Transit in Hepatic Encephalopathy
Conditions: Hepatic Encephalopathy;   Hepatitis C;   Liver Cirrhosis
Intervention: Drug: Rifaximin (drug)
Outcome Measures: Phase A: Degree of bacterial overgrowth and its correlation with the grade of hepatic Encephalopathy (if present);   Phase B: Improvement in the psychometric scores and proportion of patients who change of HE stage;   Improved Intestinal transit time;   Improvement in bacterial overgrowth;   Improved insomnia;   Improved flatulence;   Improved quality of life.
4 Recruiting Late Hypothermia for Hypoxic-Ischemic Encephalopathy
Conditions: Infant, Newborn;   Hypoxia, Brain;   Hypoxia-Ischemia, Brain;   Encephalopathy, Hypoxic-Ischemic;   Hypoxic-Ischemic Encephalopathy;   Ischemic-Hypoxic Encephalopathy
Interventions: Procedure: Hypothermia;   Procedure: Normothermic Control
Outcome Measures: Death or moderate or severe disability;   Number of deaths in the NICU and following discharge;   Number of infants with moderate and severe disability;   Number of infants with mild, moderate and severe disability;   Number of infants with any disability based on level of Encephalopathy at randomization;   Number of infants with non-CNS organ system dysfunction;   Number of infants with a DNR order;   Number of infants with a DNR order and support is withdrawn;   Number of infants with a DNR order and either die or survive;   Number of infants with neonatal seizures, with and without EEG abnormalities
5 Not yet recruiting Lactulose, L-ornithine L-aspartate, or Rifaximin Versus Placebo for Preventing Hepatic Encephalopathy in Variceal Bleeding
Condition: Hepatic Encephalopathy
Interventions: Drug: Lactulose;   Drug: L-ornithine L-aspartate;   Drug: Rifaximin;   Drug: Placebo
Outcome Measures: Development of clinical hepatic Encephalopathy;   Development of minimal hepatic Encephalopathy
6 Unknown  Efficacy of L-Ornithine L-Aspartate in Acute Hepatic Encephalopathy.
Condition: Hepatic Encephalopathy
Interventions: Drug: L-ornithine-L-aspartate;   Drug: Lactose
Outcome Measures: Sustained improvement of at least one grade in mental state based on the West Haven criteria;   Severity of hepatic Encephalopathy assessed by the West Haven criteria;   Severity of hepatic Encephalopathy assessed by the Glasgow Coma Scale;   Severity of hepatic Encephalopathy assessed by the Clinical Hepatic Encephalopathy Staging Scale (CHESS);   Decrease in venous ammonia levels;   Improvement in electroencephalographic tracing
7 Not yet recruiting Treatment of Hepatic Encephalopathy With Flumazenil and Change in Cortical GABA Levels in MRS
Conditions: Hepatic Encephalopathy;   Liver Cirrhosis
Interventions: Drug: Flumazenil;   Drug: Placebo
Outcome Measures: hepatic Encephalopathy symptoms;   flumazenil impact on functional MRI
8 Recruiting The Role of Bacterial Overgrowth and Delayed Intestinal Transit in Hepatic Encephalopathy.
Condition: Hepatic Encephalopathy
Intervention: Drug: Rifaximin
Outcome Measures: Laboratory results;   Lactulose Hydrogen Breath Test;   Quality of Life
9 Recruiting Phase 2B Efficacy/Safety of Ornithine Phenylacetate in Hospitalized Cirrhotic Patients With Hepatic Encephalopathy (STOP-HE)
Conditions: Acute Episode of Overt Hepatic Encephalopathy;   Hepatic Encephalopathy
Interventions: Drug: ornithine phenylacetate;   Drug: placebo intravenous infusion
Outcome Measures: Change from Baseline in Hepatic Encephalopathy Stage;   Change from Baseline in Modified Orientation Log;   Length of hospital stay
10 Unknown  Effect of Lactose in Patients With Chronic Liver Disease and Minimal Hepatic Encephalopathy
Conditions: Hepatic Encephalopathy;   Liver Cirrhosis
Intervention: Dietary Supplement: whole milk vs lactose-free milk
Outcome Measures: Reversion of Minimal Hepatic Encephalopathy (psychometric test);   Quality of life and blood ammonium
11 Unknown  Secondary Prophylaxis of Hepatic Encephalopathy in Cirrhosis
Condition: Hepatic Encephalopathy
Interventions: Drug: Lactulose;   Drug: Probiotics(VSL#3)
Outcome Measures: episode of overt hepatic Encephalopathy;   side effects to therapy
12 Recruiting Glutamine Challenge as Predictor of Hepatic Encephalopathy After Transjugular Intrahepatic Portosystemic Shunt (TIPS)
Conditions: Refractory Ascites;   Hepatic Hydrothorax;   Hepatic Encephalopathy;   Cirrhosis
Interventions: Other: Oral glutamine challenge;   Other: Psychometric Tests
Outcome Measures: Overt hepatic Encephalopathy;   Sarcopenia;   Physical activity;   Dietary Intake
13 Unknown  Lactulose for the Prevention of Hepatic Encephalopathy in Cirrhotic Patients With Upper Gastrointestinal Hemorrhage
Conditions: Hepatocerebral Encephalopathy;   Portal-Systemic Encephalopathy;   Encephalopathy, Hepatic;   Encephalopathy, Hepatocerebral
Interventions: Drug: Lactulose;   Drug: Placebo
Outcome Measures: Development of Clinically Overt Hepatic Encephalopathy;   Death, hospital stay
14 Recruiting The Efficacy, Safety, And Pharmacokinetics Of Rifaximin In Subjects With Severe Hepatic Impairment And Hepatic Encephalopathy
Condition: Hepatic Encephalopathy
Interventions: Drug: Placebo;   Drug: Rifaximin
Outcome Measures: Time to first Hepatic Encephalopathy(HE) breakthrough episode;   Time to first HE-related hospitalization;   All Cause Mortality
15 Unknown  Primary Prophylaxis of Hepatic Encephalopathy in Patients With Cirrhosis
Condition: Hepatic Encephalopathy
Intervention: Drug: Lactulose
Outcome Measures: prevention of first episode of hepatic Encephalopathy;   Side effects to lactulose and mortality
16 Not yet recruiting Preemie Hypothermia for Neonatal Encephalopathy
Conditions: Infant, Newborn;   Hypoxia, Brain;   Hypoxia-Ischemia, Brain;   Encephalopathy, Hypoxic-Ischemic;   Hypoxic-Ischemic Encephalopathy;   Ischemic-Hypoxic Encephalopathy
Interventions: Procedure: Hypothermia;   Procedure: Normothermic Control
Outcome Measures: Death or moderate or severe disability;   Number of deaths in the NICU and following discharge;   Differences in MRI findings after cessation of cooling/control obtained;   Number of infants with moderate and severe disability;   Causes of Death;   Neurological injury by cranial ultrasound within 24 hours of enrollment
17 Unknown  RICE Trial: Rifaximin In Chronic Hepatic Encephalopathy - A Randomized, Controlled Trial
Condition: Hepatic Encephalopathy
Intervention: Drug: Rifaximin alone, Rifaximin combined with Lactulose
Outcome Measures: Number of hospitalizations for HE;   Changes in psychometric testing during study period;   Number of hospitalization days for all causes;   Death or survival to liver transplantation;   Rate of adverse events with rifaximin treatment
18 Recruiting Magnetic Resonance Biomarkers in Neonatal Encephalopathy
Condition: Neonatal Encephalopathy
Intervention:
Outcome Measure: Prognostic accuracy of [NAA]
19 Recruiting Cord Blood for Neonatal Hypoxic-ischemic Encephalopathy
Condition: Neonatal Hypoxic Ischemic Encephalopathy
Interventions: Biological: infusion of autologous cord blood;   Other: Neurodevelopmental outcomes
Outcome Measures: Adverse event rates occurring in the pilot study population will be compared between the cord blood cell recipients and historical controls.;   Secondary endpoints of this pilot study will include preliminary efficacy as measured by neurodevelopmental function at 4 - 6 months and 9 - 12 months of age;   neuroimaging results will be collected and compared with available results from prior trials of therapies in this population, and from a previously collected set of images from normal term newborns through the first year of life.
20 Recruiting BiHiVE2 Study. The Investigation and Validation of Predictive Biomarkers in Hypoxic-ischaemic Encephalopathy.
Conditions: Hypoxic Ischaemic Encephalopathy (HIE);   Asphyxia
Intervention:
Outcome Measures: EEG confirmed hypoxic-ischaemic brain injury in the first 72 hours of life;   Neurodevelopmental outcome at 2 years of age assessed using BSID III